Liver fibrosis fast facts:

25% of worldwide population

25% of worldwide population has NAFLD1

20% of the NAFLD population and 55.5% of type 2 diabetes patients have NASH disease1

NASH continues to grow

Globally, NASH prevalence is 1.5% – 6.5%2

NASH disease is expected to increase by over 50% in the next 10 years2

NASH Economic Burden

The total cost of NASH-related care in North America will amount to $593 billion between 2013 and 20333

NAFLD encompasses the spectrum of liver disease, ranging from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis

Patients at risk of NAFLD and NASH are not always identified as there are no obvious clinical manifestations and it can remain silent for several years as it progresses

Fibrosis is becoming the main predictor of NAFLD progression to NASH and if detected at an early stage it can be prevented through lifestyle changes

Currently, there is no single alternative that can provide all the information offered by a liver biopsy – consequently, there is an urgent need for non-invasive and cost-effective biomarkers to facilitate widespread surveillance

Median’s eyonis™ NASH

Unrivalled AI/ML Software as Medical Device (SaMD) enabling liver fibrosis diagnosis with unprecedented performance

  • The only end-to-end AI/ML tech based SaMDs indicated for liver fibrosis in NASH

  • Unprecedented sensitivity and specificity performance

  • eyonis™ has the potential to identify fibrosis when still reversible

  • Additional indications

    Lung cancer

    Lung cancer screening (LCS) & incidental pulmonary nodules (IPN)

    Liver cancer

    Very early Hepatocellular Carcinoma (HCC)

    Latest news


    Median Technologies Announces Rebranding of iBiopsy®, Changes Name to eyonis™

    Median Technologies unveils a new identity, including a new name, logo, tagline for its iBiopsy® AI/ML tech-based suite of software as medical devices (SaMD) and business unit, as part of an extensive rebranding initiative. iBiopsy® becomes eyonis™.


    Median Technologies to speak at the Radiological Society of North America 2023 Annual Meeting, Nov. 26 – 30, Chicago, IL, USA

    AI Theater Presentation: “Transforming Cancer Diagnosis through End-to-End AI-Powered SaMD”


    First results of Median Technologies’ iBiopsy® HCC detection AI model developed on the PHELICAR Clinical Data Registry, to be presented at the ESMO Congress(Oct 20-24, 2023, Madrid, Spain)


    Median Technologies announces onboarding of all academic sites involved in the pivotal validation plan for iBiopsy® LCS CADe/CADx SaMD